Net profits up 23% to HK$548 million with interim dividend HK$0.05/share
Continuously kept leading position in the industry
Dynamics of R&D and bulk pharmaceuticals projects emerged
Results summary:
- Total revenue HK$2,326 million for first half year, representing an increase of 11.1% year over year
- Net profit HK$548 million, representing an...
More...
